Adding the investigational agent masitinib to standard frontline docetaxel significantly reduced the risk of disease progression or death in men with metastatic castration-resistant prostate cancer ...
Fosnight described how stigma itself becomes a barrier to care, even though effective diagnostic and treatment options are available. In an interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, ...
Take a look through the key trials investigating BCG/ICI combinations in BCG-naïve NMIBC. In BCG-naïve non–muscle invasive bladder cancer (NMIBC), emerging options are largely focused on combining BCG ...
FG-3246 targets CD46 in mCRPC patients, focusing on those who progressed on ARSI without prior taxane therapy. The trial will evaluate FG-3246's safety, efficacy, and pharmacokinetics, alongside ...
The Virtuoso Surgical Robotic System received FDA breakthrough designation for bladder lesion removal, enabling expedited development and review processes. En bloc resection improves cancer staging ...
A major focus of the discussion is the integration of advanced prostate cancer therapeutics into urology offices. In this episode of Pearls and Perspectives, Amy Pearlman, MD, speaks with Vahan ...
Ensuring consistent diagnostic quality remains critical. In this video, Veeru Kasivisvanathan, MBBS, BSc, FRCS, MSc, PGCert, PhD, discussed findings from the PRIME trial, a multicenter international ...
Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC. On September 9, 2025, the FDA approved the gemcitabine intravesical system ...
Stephen J. Freedland, MD, placed dietary guidance within the broader context of survivorship care. In discussing the links between diet and prostate cancer, Stephen J. Freedland, MD, a professor of ...
Sunobinop showed significant symptom improvement in 41% of IC/BPS patients versus 9% with placebo, indicating its potential efficacy. The investigational compound targets the NOP receptor, affecting ...
Miles-Thomas emphasized the importance of Northwestern’s thoughtful implementation strategy. In a recent interview, Henry C. Wright IV, MD, and Jennifer Miles-Thomas, MD, URPS, MBA, highlighted ...
Inlexzo, a gemcitabine intravesical system, is approved for BCG-unresponsive NMIBC, offering extended local drug delivery for up to 14 cycles. The SunRISe-1 trial showed an 82.4% complete response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback